.
 
Aliases:
Recombinant factor 7a
Novoseven RT
Novo7
Recombinant factor viia
Recombinant vii a
Recombinant 7a
Factor 7a
FVII

Topic aliases are alternate phrasings for a particular topic.


Recombinant factor VIIa concentrate developed initially for use in haemophilia patients with inhibitors to non-recombinant factor VII.

Improve to correct grammar or spelling, but do not significantly alter the substance of the original author's text.


Cancel
attachment
Endorsed by , more...
Locksmallsmush Private
Locksmallsmush only
Locksmallsmush only


Control of bleeding and surgical prophylaxis in patients with:
- inhibitors to coagulation Factors VIII or IX;
- congenital FVII deficiency;
- Glanzmann's Thrombasthenia who have antibodies to GPIIb-IIIa and or HLA, and with past or present refractoriness to platelet transfusions.

Improve to correct grammar or spelling, but do not significantly alter the substance of the original author's text.


Cancel
attachment
Endorsed by , more...
Locksmallsmush Private
Locksmallsmush only
Locksmallsmush only


For non-surgical bleeding where patient is normothermic, normal acid-base, and where FFP & cryoprecipitate have been administered.

Improve to correct grammar or spelling, but do not significantly alter the substance of the original author's text.


Cancel
attachment
Endorsed by , more...
Locksmallsmush Private
Locksmallsmush only
Locksmallsmush only


In coagulopathic patients who have undergone massive transfusion, are actively bleeding & meet usual physiological criteria, dose is 100mcg/kg refl.in/81 #improve

Improve to correct grammar or spelling, but do not significantly alter the substance of the original author's text.


Cancel
attachment
Endorsed by , more...
Locksmallsmush Private
Locksmallsmush only
Locksmallsmush only


In coagulopathic traumatic brain injury requiring urgent craniotomy, a smaller dose of 1mg (~10mcg/kg) is usually sufficient. refl.in/81 #ref #improve

Improve to correct grammar or spelling, but do not significantly alter the substance of the original author's text.


Cancel
attachment
Endorsed by , more...
Locksmallsmush Private
Locksmallsmush only
Locksmallsmush only


90mcg/kg IV 2hrly until haemostasis

Improve to correct grammar or spelling, but do not significantly alter the substance of the original author's text.


Cancel
attachment
Endorsed by , more...
Locksmallsmush Private
Locksmallsmush only
Locksmallsmush only


Significant risk of thromboembolic complications. Consider risk/benefit ratio. Thomas GOR et al J Trauma 62, 2007. #ref

Improve to correct grammar or spelling, but do not significantly alter the substance of the original author's text.


Cancel
attachment
Endorsed by , more...
Locksmallsmush Private
Locksmallsmush only
Locksmallsmush only


Binds to exposed Tissue Factor, directly activates Factor 9 into 9a and Factor 10 into 10a, and thereby initiates conversion of prothrombin to thrombin. Thrombin leads to the activation of platelets and Factors 5 and 8 at the site of injury and conversion of fibrinogen to fibrin which results in the formation of a haemostatic plug.

Improve to correct grammar or spelling, but do not significantly alter the substance of the original author's text.


Cancel
attachment
Endorsed by , more...
Locksmallsmush Private
Locksmallsmush only
Locksmallsmush only